United Capital Financial Advisers LLC boosted its holdings in shares of Zoetis Inc (NYSE:ZTS) by 57.1% in the 1st quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 18,452 shares of the company’s stock after buying an additional 6,710 shares during the quarter. United Capital Financial Advisers LLC’s holdings in Zoetis were worth $1,541,000 at the end of the most recent quarter.
Other hedge funds and other institutional investors have also made changes to their positions in the company. Navellier & Associates Inc bought a new stake in Zoetis during the fourth quarter valued at approximately $606,000. Lombard Odier Asset Management Switzerland SA grew its position in Zoetis by 13.8% during the fourth quarter. Lombard Odier Asset Management Switzerland SA now owns 279,676 shares of the company’s stock valued at $20,148,000 after buying an additional 34,000 shares during the period. IFM Investors Pty Ltd grew its position in Zoetis by 10.4% during the first quarter. IFM Investors Pty Ltd now owns 15,196 shares of the company’s stock valued at $1,269,000 after buying an additional 1,437 shares during the period. Amalgamated Bank grew its position in Zoetis by 9.5% during the fourth quarter. Amalgamated Bank now owns 64,901 shares of the company’s stock valued at $4,675,000 after buying an additional 5,633 shares during the period. Finally, Westwood Holdings Group Inc. grew its position in Zoetis by 13.3% during the fourth quarter. Westwood Holdings Group Inc. now owns 65,133 shares of the company’s stock valued at $4,692,000 after buying an additional 7,632 shares during the period. Institutional investors own 90.09% of the company’s stock.
In other news, insider Kristin C. Peck sold 4,877 shares of the business’s stock in a transaction on Tuesday, May 1st. The shares were sold at an average price of $83.46, for a total value of $407,034.42. Following the transaction, the insider now owns 42,652 shares of the company’s stock, valued at $3,559,735.92. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. 0.35% of the stock is currently owned by insiders.
Shares of Zoetis opened at $85.82 on Friday, Marketbeat reports. The company has a current ratio of 4.27, a quick ratio of 2.83 and a debt-to-equity ratio of 2.51. Zoetis Inc has a 1-year low of $59.50 and a 1-year high of $89.25. The company has a market cap of $42.11 billion, a price-to-earnings ratio of 35.76, a PEG ratio of 1.92 and a beta of 0.98.
Zoetis (NYSE:ZTS) last issued its quarterly earnings results on Wednesday, May 2nd. The company reported $0.75 earnings per share for the quarter, beating the consensus estimate of $0.69 by $0.06. Zoetis had a net margin of 17.97% and a return on equity of 68.51%. The business had revenue of $1.37 billion for the quarter, compared to the consensus estimate of $1.35 billion. During the same quarter in the previous year, the firm earned $0.53 earnings per share. The company’s revenue for the quarter was up 11.0% on a year-over-year basis. equities research analysts predict that Zoetis Inc will post 3.06 EPS for the current fiscal year.
The business also recently announced a quarterly dividend, which will be paid on Tuesday, September 4th. Stockholders of record on Friday, July 20th will be issued a $0.126 dividend. This represents a $0.50 annualized dividend and a dividend yield of 0.59%. The ex-dividend date is Thursday, July 19th. Zoetis’s dividend payout ratio (DPR) is presently 20.83%.
Several analysts recently issued reports on the stock. BMO Capital Markets restated a “hold” rating and set a $80.00 target price on shares of Zoetis in a research report on Wednesday, May 16th. Morgan Stanley lowered shares of Zoetis from an “overweight” rating to an “equal weight” rating and set a $70.00 target price for the company. in a research report on Monday, March 19th. They noted that the move was a valuation call. Jefferies Financial Group restated a “buy” rating and set a $96.00 target price on shares of Zoetis in a research report on Friday, April 13th. Cantor Fitzgerald set a $98.00 target price on shares of Zoetis and gave the company a “buy” rating in a research report on Wednesday, June 6th. Finally, Hilliard Lyons lowered shares of Zoetis to a “neutral” rating in a research report on Thursday, April 19th. They noted that the move was a valuation call. One research analyst has rated the stock with a sell rating, seven have issued a hold rating and eleven have issued a buy rating to the company’s stock. The company currently has a consensus rating of “Buy” and a consensus target price of $84.73.
Zoetis Company Profile
Zoetis Inc discovers, develops, manufactures, and markets veterinary vaccines and medicines in the United States and internationally. It commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep; and companion animals comprising dogs, cats, and horses.
Want to see what other hedge funds are holding ZTS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Zoetis Inc (NYSE:ZTS).
Receive News & Ratings for Zoetis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zoetis and related companies with MarketBeat.com's FREE daily email newsletter.